Complement Factor H Deficiency: A Patient Guide

Complement Factor H (CFH) deficiency is a rare condition that fundamentally changes how your immune system interacts with your own body. To understand this condition, it helps to view your immune system as a high-powered engine that is designed to stay “idling” at all times so it can respond instantly to infections. Because this engine is so powerful, it requires a sophisticated set of “brakes” to prevent it from overheating or damaging the healthy tissues around it. Factor H is one of the most critical brakes in this system, and when it is missing or broken, the immune system can stay stuck in an “on” position, leading to unintended damage to the kidneys, the blood vessels, and the eyes ^[1][2].

It is important to note that “CFH deficiency” is an umbrella term covering several biologically distinct situations: complete Factor H deficiency, heterozygous CFH variants that create a susceptibility but may have normal Factor H levels, and acquired anti-Factor H autoantibodies.

This imbalance does not look the same for everyone; instead, it tends to show up in one of three primary ways depending on where the immune system’s overactivity is most intense, though these phenotypes can overlap and are not mutually exclusive destinations. In some people, it manifests as Atypical Hemolytic Uremic Syndrome (aHUS), where the complement-mediated injury to the lining of small blood vessels creates tiny clots that can suddenly impair kidney function. In others, it appears as C3 Glomerulopathy (C3G), a process where immune proteins accumulate in the kidney’s filters like silt in a pipe, leading to inflammation and scarring. Finally, because the same protective protein is needed in the back of the eye, some individuals may develop retinal deposits that can affect vision, similar to an early-onset form of macular degeneration ^[3][4]. Retinal disease, however, is not an expected feature for every patient.

The reason these “brakes” fail usually falls into one of two categories, which serves as the primary roadmap for your medical team. Some people are born with a genetic variation that creates a susceptibility to impaired Factor H regulation, while others develop an autoimmune response where the body mistakenly creates antibodies that block the protein from doing its job. Distinguishing between these “inherited” and “acquired” forms is a priority for your doctors, as it determines whether the best strategy is to use medications that physically block the complement system’s final attack stage or to use specialized procedures to filter the harmful antibodies out of your blood ^[5][6]. Treatment depends heavily on the actual phenotype, severity, and kidney status.

While a diagnosis of CFH deficiency marks the beginning of a complex journey, it also marks the end of the mystery surrounding your symptoms. In the past, these conditions were difficult to manage because their underlying cause wasn’t well understood. Today, because we can pinpoint exactly where the immune system has lost its balance, we have targeted treatments that block terminal complement downstream (like eculizumab and ravulizumab) to prevent endothelial injury in appropriate aHUS patients, while C3G and autoantibody disease may involve different targeted therapies. By working closely with a specialized care team, you can move from a state of medical crisis into a focused plan of long-term monitoring, allowing you to protect your health while the science of the complement system continues to advance ^[7][8].